David Mandarich compensation by year
M.D.C. Summary Compensation Table · all 3 fiscal years held| Component | FY2020 | FY2021 | FY2022 |
|---|---|---|---|
| Salary | $830,000 | $1,000,000 | $1,000,000 |
| Stock awards | $7,117,543 | $9,982,336 | $1,999,966 |
| Option awards | $1,885,060 | $0 | $6,674,320 |
| Non-equity incentive | $4,000,000 | $6,000,000 | $6,000,000 |
| Pension and deferred compensation | $0 | $0 | $0 |
| All other | $90,279 | $10,279 | $9,060 |
| Total | $13,922,882 | $16,992,615 | $15,683,346 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: M.D.C. Holdings, Inc. DEF 14A filed March 1, 2023, accession 0000773141-23-000013, and prior-year filings. Open the filing on EDGAR.
How this page was built: the M.D.C. Holdings, Inc. filed document, accession 0000773141-23-000013. Every figure is read from that document and cited to the page and table it appears in. Filed March 1, 2023.
Equity holdings
unvested awards at FY2022 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| PSU | 259,200 | $8,190,720 | — |
| PSU | 90,000 | $2,844,000 | — |
| RSU | 42,835 | $1,353,586 | — |
| RSU | 25,540 | $807,064 | — |
| RSU | 16,525 | $522,190 | — |
| Option | 72,000 | — | $23.90 |
| Option | 800,000 | — | $28.78 |
Per the Outstanding Equity Awards at Fiscal Year-End table in M.D.C. Holdings, Inc.'s FY2022 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
14 Form 4 lines since the FY2022 proxy (filed March 1, 2023)current to 2026-11-21 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2024-04-19 | Disposition to the issuer | — | 63,868 | — | 0 |
| 2024-04-19 | Disposition to the issuer derivative | — | 233,280 | — | 0 |
| 2024-04-19 | Disposition to the issuer derivative | — | 800,000 | — | 0 |
| 2024-04-19 | Disposition to the issuer | — | 4,142,970 | — | 0 |
| 2024-04-19 | Disposition to the issuer | — | 360,000 | — | 0 |
| 2024-04-19 | Disposition to the issuer derivative | — | 216,000 | — | 0 |
| 2024-04-19 | Disposition to the issuer derivative | — | 216,000 | — | 0 |
| 2024-03-07 | Gift | — | 320,000 | $0.00 | 4,206,838 |
The 8 most recent of 14 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
M.D.C.’s named executive officers, FY2022
as the company reported each| Named executive officer | Role | FY2022 total |
|---|---|---|
| Larry Mizel | Executive Chairman | $18,512,436 |
| David Mandarich · this page | President and Chief Executive Officer | $15,683,346 |
| Robert Martin | Senior Vice President and Chief Financial Officer | $4,359,386 |
| Michael Kaplan | Senior Vice President and General Counsel | $516,455 |
| Rebecca Givens | Senior Vice President and General Counsel | $269,104 |
Board service
M.D.C. board · FY2022How this board is paid
Company policy: M.D.C. pays directors a $60,000 cash retainer. As stated in M.D.C.'s FY2022 proxy.
The full M.D.C. compensation record
free company briefThis page is one person within M.D.C.'s record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the M.D.C. proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are M.D.C.'s own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.